HealthcareServices

Chlamydia Market Forecast 2026–2035: How to Leverage Market Growth

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the chlamydia market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Chlamydia Market’s size between 2026 and 2030?

The chlamydia market size has experienced strong expansion in recent years. It is projected to increase from $3.23 billion in 2025 to $3.51 billion in 2026, at a compound annual growth rate (CAGR) of 8.8%. The growth observed in previous periods can be linked to the increasing prevalence of sexually transmitted infections, the expansion of public health screening initiatives, enhanced access to diagnostic laboratories, rising awareness surrounding reproductive health, and the availability of various antibiotic treatment options.

The chlamydia market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $4.86 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This growth throughout the forecast period stems from factors such as the increasing demand for point-of-care diagnostics, a heightened emphasis on preventive sexual healthcare, the expansion of digital health screening platforms, escalating investments in diagnostic innovation, and the proliferation of government-led STI control programs. Key trends shaping the forecast period encompass the increasing adoption of rapid chlamydia testing methods, a growing reliance on NAAT-based diagnostic techniques, an intensified focus on early STI screening initiatives, the development of home-based testing solutions, and improved awareness concerning asymptomatic infections.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21138&type=smp

Which Drivers Are Shaping Strategic Decisions In The Chlamydia Market?

The escalating incidence of sexually transmitted diseases is projected to stimulate the expansion of the chlamydia market moving forward. Sexually transmitted diseases (STDs) are infections that propagate through sexual contact, encompassing conditions like chlamydia, gonorrhea, and HIV. The uptick in STDs is attributed to elements such as reduced condom utilization, inadequate public awareness, restricted access to healthcare services, and the widespread use of dating applications that foster multiple sexual relationships. Addressing chlamydia helps mitigate the dissemination of STDs by eliminating the infection, averting potential complications, and diminishing the likelihood of transmission to sexual partners. By way of illustration, in October 2025, the Minority HIV/AIDS Fund (MHAF), a US-based government agency, estimated that in 2023, around 39.9 million people globally were living with HIV, encompassing 38.6 million adults and 1.4 million children, a statistic compared to figures from earlier years. Thus, the rising occurrence of sexually transmitted diseases is a key driver for the growth of the chlamydia market.

What Segment Classifications Make Up The Chlamydia Market?

The chlamydia market covered in this report is segmented –

1) By Test Type: Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, Other Test Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Culture Tests: Urethral Swab Culture, Endocervical Swab Culture, Urine Culture Test, Conjunctival Swab Culture

2) By Nucleic Acid Amplification Test (NAAT): PCR (Polymerase Chain Reaction), Transcription-Mediated Amplification (TMA), Strand Displacement Amplification (SDA), Loop-Mediated Isothermal Amplification (LAMP)

3) By Direct Fluorescent Antibody Test: DFA Test For Urogenital Chlamydia, DFA Test For Ocular Chlamydia, DFA For Respiratory Chlamydia Detection

4) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Western Blot

5) By Other Test Types: Immunochromatographic Rapid Test, Lateral Flow Immunoassay, Hybrid Capture Test (HCT)

What Long-Term Trends Are Expected To Shape The Future Of The Chlamydia Market?

Major entities operating within the chlamydia market are prioritizing the development of innovative solutions, such as the expansion of point-of-care molecular diagnostics. This aims to enable faster, more accurate onsite detection and improve the timeliness of treatment outcomes. The term point-of-care molecular diagnostics expansion denotes the wider implementation of rapid, immediate molecular tests that allow for the detection of infections like chlamydia without relying on centralized laboratory facilities. For instance, in January 2025, F. Hoffmann-La Roche AG, a healthcare company based in Switzerland, obtained FDA 510(k) clearance and a CLIA waiver for its cobas liat molecular tests. These specific tests are engineered for diagnosing sexually transmitted infections (STIs) directly at the point of care. They incorporate multiplex assay panels designed to detect and differentiate multiple STIs, including chlamydia, gonorrhea, and Mycoplasma genitalium, from a single patient sample, with results becoming available in 20 minutes or less.

Which Major Firms Are Strengthening Their Position In The Chlamydia Market?

Major companies operating in the chlamydia market are Siemens Healthineers, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Hologic Inc, Quidel Corporation, Bio-Rad Laboratories Inc, Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co Ltd, MedMira Inc, GenMark Diagnostics Inc, ACON Laboratories Inc, Biocartis Group NV, Inova Diagnostics Inc, Trinity Biotech Plc, Seegene Inc, Qiagen NV, Binx Health Inc, Chembio Diagnostics Inc, Visby Medical Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chlamydia-global-market-report

Which Regions Are Poised For Strategic Growth In The Chlamydia Market?

North America was the largest region in the chlamydia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chlamydia Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21138&type=smp

Browse Through More Reports Similar to the Global Chlamydia Market 2026, By The Business Research Company

Sexually Transmitted Infections Stis Market Report 2026

https://www.thebusinessresearchcompany.com/report/sexually-transmitted-infections-stis-global-market-report

Chlamydia Infection Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chlamydia-infection-treatment-global-market-report

Chlamydia Infection Diagnostics And Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/chlamydia-infection-diagnostics-and-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795